It has been a wild ride. After years of outperforming the S&P 500, the biotech sector found itself seriously affected in the recent market correction.
Substantial investments made during the last few years resulted in a vibrant biotech community with a healthy flow of safe and effective new drugs.
Much remains to be accomplished in the translation of promising candidates into approved products and its impact on the city of New York—which has been offering generous benefits for technology entrepreneurs—as it reaffirms its intent to become a world center for biotech innovation. April 7 is your opportunity to hear the insights of biotech experts about the challenges and opportunities in this exciting field.
